{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T08:38:54Z","timestamp":1768552734915,"version":"3.49.0"},"posted":{"date-parts":[[2022,1,7]]},"group-title":"Epidemiology","reference-count":21,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2022,1,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Healthcare workers (HCW) were amongst the first prioritized for COVID-19 vaccination but data on COVID-19 vaccine effectiveness among HCW is still limited. This study aims to estimate the COVID-19 vaccine effectiveness (VE) against SARS-CoV-2 symptomatic infection among HCW from Portuguese hospitals.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this prospective cohort study, we analysed data from HCW (all professional categories) from two central hospitals in the Lisbon and Tagus Valley and Centre regions of mainland Portugal between December 2020 and November 2021. VE against symptomatic SARS-CoV-2 infection was estimated as one minus the confounder adjusted hazard ratios by Cox models considering age group, sex, presence of chronic disease and occupational exposure to patients diagnosed with COVID-19 as adjustment variables.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>During the 11 months of follow up, the 2213 HCW contributed a total of 1950 person-years at risk and 171 SARS-CoV-2 events occurred. The COVID-19 incidence rate for unvaccinated HCW was 348.7 per 1000 person-years while for fully vaccinated HCW was 43.0 per 1000 person-years. We observed a VE against symptomatic SARS-CoV-2 infection of 73.9% (95% CI: 26.2\u201390.8%) for complete vaccination status.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This cohort study found a high COVID-19 VE against symptomatic SARS-CoV-2 infection in Portuguese HCW, which is in concordance with previous studies from other countries. Monitoring of VE in this HCW cohort continues during the winter 2021\/2022 to evaluate potential VE decay and booster vaccine effect.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2022.01.07.22268889","type":"posted-content","created":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T15:25:16Z","timestamp":1641655516000},"source":"Crossref","is-referenced-by-count":1,"title":["COVID-19 vaccine effectiveness among healthcare workers in Portugal: results from a hospital-based cohort study, December 2020 to November 2021"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7626-4991","authenticated-orcid":false,"given":"V\u00e2nia","family":"Gaio","sequence":"first","affiliation":[]},{"given":"Adriana","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Palmira","family":"Amaral","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o Faro","family":"Viana","sequence":"additional","affiliation":[]},{"given":"Pedro Pinto","family":"Leite","sequence":"additional","affiliation":[]},{"given":"Carlos Matias","family":"Dias","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5772-2416","authenticated-orcid":false,"given":"Irina","family":"Kislaya","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6230-7209","authenticated-orcid":false,"given":"Baltazar","family":"Nunes","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1849-1499","authenticated-orcid":false,"given":"Ausenda","family":"Machado","sequence":"additional","affiliation":[]}],"member":"54368","reference":[{"key":"2022011021400447000_2022.01.07.22268889v1.1","unstructured":"World Health Organization. COVID-19 situation in the WHO European Region (accessed November 17, 2021) Available from: https:\/\/who.maps.arcgis.com\/apps\/opsdashboard\/index.html#\/ead3c6475654481ca51c248d52ab9c61."},{"key":"2022011021400447000_2022.01.07.22268889v1.2","doi-asserted-by":"publisher","DOI":"10.1186\/s40249-021-00915-3"},{"key":"2022011021400447000_2022.01.07.22268889v1.3","unstructured":"WHO sage roadmap for prioritizing uses of COVID-19 Vaccines in the context of limited supply. (accessed February 1, 2021). Available from: https:\/\/www.who.int\/docs\/default-source\/immunization\/sage\/covid\/sage-prioritization-roadmap-covid19-vaccines.pdf\u00e3Status=Temp&sfvrsn=bf227443_2"},{"key":"2022011021400447000_2022.01.07.22268889v1.4","unstructured":"Health workers at risk, older adults and residents of long-term care facilities to be prioritized for COVID-19 vaccination. WHO\/Europe website (accessed February 1, 2021). Available from: https:\/\/www.euro.who.int\/en\/health-topics\/health-emergencies\/coronavirus-covid-19\/news\/news\/2020\/11\/health-workers-at-risk,-older-adults-and-residents-of-long-term-care-facilities-to-be-prioritized-for-covid-19-vaccination"},{"key":"2022011021400447000_2022.01.07.22268889v1.5","unstructured":"Minist\u00e9rio da Sa\u00fade. Plano de Vacina\u00e7\u00e3o contra a COVID-19. Lisboa, Portugal; 2020. (Accessed November 10, 2021). Available from: https:\/\/www.sns.gov.pt\/wp-content\/uploads\/2021\/01\/Apresentacao_PlanoVacinacao_2020.01.28_VFINAL.pdf"},{"key":"2022011021400447000_2022.01.07.22268889v1.6","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2020.19328"},{"key":"2022011021400447000_2022.01.07.22268889v1.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108891"},{"key":"2022011021400447000_2022.01.07.22268889v1.8","unstructured":"Pouwels KB , Pritchard E , Matthews PC , Stoesser N , Eyre DW , Vihta K-D , et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med [Internet]. 2021 Oct 14 [cited 2021 Nov 1]; Available from: https:\/\/www.nature.com\/articles\/s41591-021-01548-7"},{"key":"2022011021400447000_2022.01.07.22268889v1.9","doi-asserted-by":"crossref","unstructured":"Goldberg Y , Mandel M , Bar-On YM , Bodenheimer O , Freedman L , Haas EJ , et al. Waning Immunity after the BNT162b2 Vaccine in Israel. N Engl J Med. 2021 Oct 27; NEJMoa2114228.","DOI":"10.1056\/NEJMoa2114228"},{"issue":"13","key":"2022011021400447000_2022.01.07.22268889v1.10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.15585\/mmwr.mm7013e3","article-title":"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers \u2014 Eight U.S. Locations, December 2020\u2013March 2021","volume":"70","year":"2021","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"2022011021400447000_2022.01.07.22268889v1.11","doi-asserted-by":"crossref","unstructured":"Moustsen-Helms IR , Emborg HD , Nielsen J et al. Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term care facility residents and healthcare workers \u2013 a Danish cohort study. 2021. MedRxiv.","DOI":"10.1101\/2021.03.08.21252200"},{"key":"2022011021400447000_2022.01.07.22268889v1.12","unstructured":"Swift MD , Breeher LE , Tande AJ et al. Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare personnel. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2021."},{"issue":"17","key":"2022011021400447000_2022.01.07.22268889v1.13","first-page":"2100420","article-title":"Effectiveness of the Comirnaty (BNT162b2, BioNTech\/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021","volume":"26","year":"2021","journal-title":"Eurosurveillance"},{"issue":"34","key":"2022011021400447000_2022.01.07.22268889v1.14","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.15585\/mmwr.mm7034e4","article-title":"Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance \u2014 Eight U.S. Locations, December 2020\u2013August 2021","volume":"70","year":"2021","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"2022011021400447000_2022.01.07.22268889v1.15","unstructured":"World Health Organization. Cohort study to measure COVID-19 vaccine effectiveness among health workers in the WHO European Region. 2021. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/340217\/WHO-EURO-2021-2141-41896-57484-eng.pdf"},{"key":"2022011021400447000_2022.01.07.22268889v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2012.10.006"},{"key":"2022011021400447000_2022.01.07.22268889v1.17","unstructured":"WHO COVID-19: Case Definitions. Published 16 Dec 2020 https:\/\/apps.who.int\/iris\/rest\/bitstreams\/1322790\/retrieve."},{"key":"2022011021400447000_2022.01.07.22268889v1.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00677-2"},{"issue":"38","key":"2022011021400447000_2022.01.07.22268889v1.19","first-page":"2100833","article-title":"mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: a cohort study based on data linkage of national health registries in Portugal, February to August 2021","volume":"26","year":"2021","journal-title":"Eurosurveillance"},{"key":"2022011021400447000_2022.01.07.22268889v1.20","doi-asserted-by":"crossref","unstructured":"Lan FY , Sidossis A , Iliaki E et al. Continued Effectiveness of COVID-19 Vaccination among Urban Healthcare Workers during Delta Variant Predominance. 2021. MedRxiv.","DOI":"10.1101\/2021.11.15.21265753"},{"key":"2022011021400447000_2022.01.07.22268889v1.21","unstructured":"Instituto Nacional de sa\u00fade Doutor Ricardo Jorge. (2021a). Covid-19: curva epid\u00e9mica e par\u00e2metros de transmissibilidade Categoria - INSA. Retrieved December 17, 2021, from https:\/\/www.insa.min-saude.pt\/category\/areas-de-atuacao\/epidemiologia\/covid-19-curva-epidemica-e-parametros-de-transmissibilidade\/"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2022.01.07.22268889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:33:31Z","timestamp":1768487611000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2022.01.07.22268889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,7]]},"references-count":21,"URL":"https:\/\/doi.org\/10.1101\/2022.01.07.22268889","relation":{},"subject":[],"published":{"date-parts":[[2022,1,7]]},"subtype":"preprint"}}